Research Article

Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population

Vadim Stepanov,1,2 Andrey Marusin,1 Kseniya Vagaitseva,1,2 Anna Bocharova,1 and Oksana Makeeva1,3

1Institute of Medical Genetics, Tomsk National Medical Research Center, Tomsk, Russia
2Tomsk State University, Tomsk, Russia
3Nebbiolo Center for Clinical Trials, Tomsk, Russia

Correspondence should be addressed to Vadim Stepanov; vadim.stepanov@medgenetics.ru

Received 1 October 2017; Accepted 22 November 2017; Published 12 December 2017

1. Introduction

The single-nucleotide polymorphisms (SNPs) in the CUB and Sushi multiple domains-1 (CSMD1) gene were recently identified in genome-wide association studies (GWAS) as significant genetic markers for schizophrenia (SZ) and cognitive performance. CSMD1 gene spanning over 2.6 Mb on chromosome 8p23.2 is highly expressed in the central nervous system and epithelial tissues [1] and encodes an important cell adhesion molecule involved in the development, connection, and plasticity of brain circuits. Despite the fact that the exact role of CSMD1 in neurodevelopmental process is not clear, murine models indicate that CSMD1 knockout induces behaviors reminiscent of blunted emotional responses, anxiety, and depression, suggesting an influence of the CSMD1 on psychopathology and endophenotypes of the negative symptom spectra [2]. A common intrinsic CSMD1 variant, rs10503253, was reported as genome-wide significant for SZ by Schizophrenia Psychiatric Genome-Wide Association Study Consortium [3] and was subsequently replicated in other GWA and meta-analysis studies [4–6]. A minor allele “A” of rs10503253 is associated with deleterious effects across a number of neurocognitive phenotypes, such as poorer performance on neuropsychological measures of general cognitive ability and memory function in SZ patients [7], and affects general cognitive ability and executive function in healthy individuals [8]. Another intrinsic variant in CSMD1, rs2616984, located 302 kb away, was found as genome-wide significant for the performance on standardized cognitive tests [9]. Recently we have demonstrated the association of the latter genetic variant with both SZ and Alzheimer’s disease in a Russian population [10, 11]. These data suggested that neuropsychological effects of CSMD1 and the plausible role of its genetic variation in schizophrenia and other neuropsychiatric diseases are based on common underlying neurological mechanism developed via cognitive endophenotypes. In this study, we investigated the role of common genetic variation in CSMD1 gene in cognitive performance in normal elderly population.
In each participant, the cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). MoCA measures 8 cognitive domains: memory, attention, naming, visuospatial/executive, language, abstraction, delayed recall, and orientation domains. MoCA scores ranged between 0 and 30 points, and higher scores indicate better cognitive function.

Genotyping of 2 genetic variants in CSMD1 gene, rs1050325 and rs2616984, was performed by multiplex PCR with the following iPLEX primer extension reaction and detection of allele-specific extension products by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry on Sequenom MassARRAY 4 platform. Details of the genotyping method have been previously described elsewhere [14].

Linkage disequilibrium (LD) between genetic variants and haplotype frequencies were estimated using Haploview 4.2 software. Statistical analysis of relationships between genetic markers and cognitive performance was performed in Statistica 7.0 (StatSoft Inc.) package using parametric (analysis of variance, ANOVA) and nonparametric (Kruskal-Wallis test and median test) statistics. For ANOVA analysis, MoCA scores were adjusted for age and education using linear regression model. Differences in allele and genotype frequencies between quartiles of MoCA distribution were estimated by chi-square test.

### 3. Results

Allele and haplotype frequencies of rs1050325 and rs2616984 in the total sample of 708 elderly subjects, as well as in the first (MoCA < 21) and fourth (MoCA > 24) quartiles of MoCA scores distribution, are presented in Table 2. Genotype distribution for both genetic variants in CSMD1 gene corresponded to Hardy-Weinberg equilibrium. No difference in the allele frequency between men and women was found. Minor alleles of both SNPs demonstrated very similar frequency in the total sample: 0.267 for “A” allele of rs1050325 and 0.272 for “G” allele of rs2616984. Two intronic variants in CSMD1 gene, located 302 kb apart, show very low level of linkage disequilibrium ($D^2 = 0.017$; LOD = 0.24).

Significantly higher frequency of the major allele of rs2616984 (“A”) was observed in a subsample of individuals with MoCA score less than 21 compared to fourth quartile's subsample (0.754 versus 0.674; chi-square = 6.008; $p = 0.014$), while no significant differences between lower and upper quartiles were found for rs1050325.

Odds ratio values for lower MoCA score associated with allele “A” and genotype “AA” of rs2616984 were 1.49 (95% CI 1.07–2.07, $p = 0.014$) and 1.70 (95% CI 1.11–2.61, $p = 0.009$), respectively. Genotype “AG” of rs2616984 and haplotype “CG” of rs105032/rs2616984 were associated with higher MoCA score (Table 3).

One-way ANOVA demonstrates no significant differences in the mean MoCA scores among genotypes of both genetic variants in CSMD1 gene, as well as among combinations of genotypes of two SNPs (Table 4). However, the effect of rs2616984 on MoCA scores was close to statistically significant ($F = 2.814$, $p = 0.060$).

### 2. Material and Methods

708 elderly individuals of European Russian descent without dementia and neurological diseases were recruited from a population-based cohort study on primary prevention of Alzheimer’s disease in Tomsk, Russia [12, 13]. The sample consisted of 74% of females (see Table 1). Mean age in the sample was 70.9 (ranging from 60 to 89) years. Level of education of the study participants was assessed with two measures: number of years of education and achieved level of education. Level of education was relatively high with 42% of study participants having bachelor’s or master’s degree and 7% having doctoral degree. Only 7% of the sample had been exposed to memory testing previously with clinical or research purpose reasons.

Health characteristics are presented in Table 1. Health conditions were self-reported with the notice from investigator to report only on diagnoses established by medical doctors and confirmed in medical records. The sample had high prevalence of cardiovascular conditions with high blood pressure indicated in 81% of study subjects.

| Characteristics                                      | Mean ± SD or % where indicated |
|------------------------------------------------------|--------------------------------|
| Age, years                                           | 70.9 ± 5.7                     |
| Gender, female                                       | 74%                            |
| Education                                            |                                |
| Years of education                                   | 13.3 ± 3.1                     |
| Min education, years                                 | 4                              |
| Max education, years                                 | 20                             |
| Maximum achieved level of education                  |                                |
| Less than high school graduate                       | 11%                            |
| High school graduate                                 | 8%                             |
| Some college or associate’s degree                   | 32%                            |
| Bachelor’s degree                                    | 42%                            |
| Master’s or higher professional degree               | 7%                             |
| Doctoral degree                                      |                                |
| Memory testing history                               | 7%                             |
| Clinical reasons                                     | 3%                             |
| Research participant                                 | 3%                             |
| Health characteristics                               |                                |
| Coronary artery disease                              | 44%                            |
| Atrial fibrillation                                  | 24%                            |
| Stroke                                               | 7%                             |
| Congestive heart failure                             | 17%                            |
| High blood pressure                                  | 81%                            |
| Obesity                                              | 26%                            |
| Diabetes, type 2                                     | 18%                            |
| Smoking                                              |                                |
| Smoking during last 30 days                          | 9%                             |
| Smoking more than 100 cigarettes over life           | 20%                            |

### Table 1: Demographic and health characteristics of the sample.
Table 2: Allele and haplotype frequency of two CSMD1 genetic variants in the total sample and in the lower (Q1) and upper (Q4) quartiles of the MoCA distribution.

| Allele, haplotype | Total sample, N = 708 | Lower quartile (MoCA ≤ 20), N = 188 | Upper quartile (MoCA ≥ 25), N = 193 | Q1 versus Q4, p |
|-------------------|----------------------|--------------------------------------|--------------------------------------|-----------------|
|                   |                      | rs1050325                            | rs2616984                            |                 |
| C                 | 0.733                | 0.741                                | 0.749                                | 0.799           |
| A                 | 0.267                | 0.259                                | 0.251                                |                 |
|                   |                      | rs1050325                            | rs2616984                            |                 |
| A                 | 0.726                | 0.754                                | 0.674                                | 0.014           |
| G                 | 0.274                | 0.246                                | 0.326                                |                 |
|                   |                      | rs1050325/rs2616984 haplotypes        |                                      |                 |
| CA                | 0.524                | 0.557                                | 0.497                                | 0.101           |
| CG                | 0.209                | 0.184                                | 0.251                                | 0.024           |
| AA                | 0.201                | 0.197                                | 0.176                                | 0.455           |
| AG                | 0.065                | 0.062                                | 0.075                                | 0.478           |

Table 3: Odds ratio values for lower MoCA score for alleles, genotypes, and haplotypes of CSMD1 genetic variants in comparison of lower (Q1) and upper (Q4) quartiles of MoCA score distribution.

| Allele, genotype, haplotype | OR       | 95% CI     | Chi-square | p      |
|-----------------------------|----------|------------|------------|--------|
|                            | rs1050325|            |            |        |
| A                           | 1.04     | 0.74–1.46  | 0.06       | 0.799  |
| C                           | 0.96     | 0.68–1.35  | 0.06       | 0.799  |
| AA                          | 0.95     | 0.42–2.16  | 0.01       | 0.905  |
| CA                          | 1.13     | 0.73–1.76  | 0.34       | 0.562  |
| CC                          | 0.90     | 0.58–1.37  | 0.29       | 0.592  |
|                            | rs2616984|            |            |        |
| A                           | 1.49     | 1.07–2.07  | 6.01       | 0.014  |
| G                           | 0.67     | 0.48–0.94  | 6.01       | 0.0142 |
| AA                          | 1.70     | 1.11–2.61  | 6.64       | 0.0099 |
| AG                          | 0.65     | 0.42–1.00  | 4.25       | 0.039  |
| GG                          | 0.70     | 0.32–1.51  | 0.96       | 0.326  |
|                            | rs1050325/rs2616984 haplotypes |                |            |        |
| CA                          | 1.27     | 0.94–1.70  | 2.63       | 0.105  |
| CG                          | 0.67     | 0.47–0.97  | 4.97       | 0.026  |
| AA                          | 1.15     | 0.79–1.69  | 0.59       | 0.443  |
| AG                          | 0.81     | 0.44–1.47  | 0.55       | 0.457  |

Significant values are in bold.

In addition, less conservative nonparametric statistics indicate that genetic variation in rs2616984 locus significantly influenced the MoCA values in the normal elderly population. Under codominant model, p value for median test was 0.024 and Kruskal-Wallis p was 0.020. No significant association of rs1050325 with MoCA scores was observed using both parametric and nonparametric statistics. Significant combined effect of two-locus CSMD1 genotypes on MoCA scores was demonstrated by median test (chi-square = 16.19; df = 8; p = 0.039).

4. Discussion

Current data on contribution of CSMD1 genetic variation to neuropsychiatric diseases and to cognitive performance are quite controversial. More evidence is accumulated on rs1050325, which is genome-wide significant marker for SZ in Europeans according to initial GWAS and subsequent replicative studies (see above), but is not replicated for Japanese [15] and Han Chinese [16]. Association of this genetic variant with cognitive and memory functions initially reported for European SZ patients [7] was confirmed for normal Greek population, but was not replicated in Norwegian healthy cohort [17]. Another intronic variant in CSMD1, rs2616984, was associated with cognitive performance in European GWAS [9] and recently was found as susceptibility marker for both SZ and Alzheimer’s disease in Russians [10, 11], but not in Central Asian Kazakh population [18]. Other CSMD1 SNPs were also reported to be associated with cognitive and memory functions in healthy Norwegians [17],
Table 4: One-way ANOVA analysis of MoCA scores among genotypes of genetic variants in CSMD1 gene.

| Genotype | N   | MoCA mean | MoCA std. deviation |
|----------|-----|-----------|---------------------|
| rs1050325, F = 0.105, p = 0.899 |     |           |                     |
| CA       | 247 | 22.08502  | 3.747744            |
| AA       | 57  | 22.35088  | 3.319269            |
| CC       | 370 | 22.14595  | 4.159463            |
| All      | 674 | 22.14095  | 3.942305            |
| rs2616984, F = 2.814, p = 0.060 |     |           |                     |
| AA       | 361 | 21.81717  | 3.966503            |
| AG       | 255 | 22.57255  | 3.928699            |
| GG       | 57  | 22.31579  | 3.728069            |
| All      | 673 | 22.14562  | 3.943373            |
| rs1050325/rs2616984, F = 0.860, p = 0.549 |     |           |                     |
| AA/AA    | 37  | 22.43243  | 3.484414            |
| CA/AA    | 126 | 21.70635  | 3.655281            |
| CC/AA    | 198 | 21.77273  | 4.239512            |
| AA/AG    | 16  | 22.25000  | 3.193744            |
| CA/AG    | 100 | 22.55000  | 3.957795            |
| CC/AG    | 139 | 22.62590  | 4.005926            |
| AA/GG    | 3   | 23.00000  | 2.645751            |
| CA/GG    | 21  | 22.14286  | 3.119066            |
| CC/GG    | 33  | 22.36364  | 4.211726            |
| All      | 673 | 22.14562  | 3.943373            |

with cognitive decline in Alzheimer’s disease in patients of European descent [19], as well as with clinical outcomes of SZ in Japanese [20].

Between-population variability in CSMD1 effects on neurocognitive phenotypes may reflect population-specific composition of genetic risk factors and/or population-specific LD patterns of associated markers with unknown functional variant(s) within CSMD1 or in adjacent genetic loci. But, nevertheless, growing amount of data on CSMD1 genetic association with various neuropsychological traits clearly indicates that structural variability at this part of the genome is likely a part of the common neurological mechanism, underlying various diseases and normal variability in neurocognitive traits. Genetic overlapping over these traits may be mediated by cognitive endophenotypes, such as variability in normal cognitive performance due to normal functional differences in brain structure and functions. This point finds support in several functional studies, demonstrating that SZ risk variants show greater effects at the level of imaging based metrics of brain structure and function than at the level of behavior [21]. Particularly, CSMD1 rs1050325 “A” allele was associated with comparatively reduced cortical activation in the middle occipital gyrus and cuneus during performance of a spatial working memory task [22].

Along with population- and genetic background-related effects, age-related differences also may play a substantial role in the variability in genetic patterns of neurocognitive traits. Association of CSMD1 variants with Alzheimer’s disease probably suggests that some part of genetic susceptibility at this locus may appear in the older age, compared to SZ susceptibility variants, but may be expressed in earlier preclinical stages as markers of cognitive and memory performance. However currently we cannot delineate possible molecular mechanisms underlying the age-related difference in CSMD1 effects on neurocognitive functions. The cohort tested in the present study is, to the best of our knowledge, the oldest sample ever used for CSMD1 genetic associations with neurocognitive phenotypes. We observed the association with MoCA performance for the genetic variant previously found to be associated with cognitive functions in younger people [9], as well as with late-onset Alzheimer’s disease in our previous work [10]. Thus the findings reported in the current paper support the growing amount of evidence for significant role of CSMD1 in normal and pathological cognitive phenotypes.

5. Conclusions

Our study suggests that genetic variants in CSMD1 gene are likely a part of genetic component of cognitive performance in the elderly.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was funded by the Russian Scientific Foundation (Project no. 16-15-00020).
References

[1] D. M. Kraus, G. S. Elliott, H. Chute et al., “CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues,” The Journal of Immunology, vol. 176, no. 7, pp. 4419–4430, 2006.

[2] V. M. Steen, C. Nepal, K. M. Ersland et al., “Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1,” PLoS ONE, vol. 8, no. 11, Article ID e79501, 2013.

[3] Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, “Genome-wide association study identifies five new schizophrenia loci,” Nature, vol. 18, no. 43, pp. 969–976, 2011.

[4] Cross-Disorder Group of the Psychiatric Genomics Consortium, “Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis,” The Lancet, vol. 381, no. 9875, pp. 1371–1379, 2013.

[5] Schizophrenia Working Group of the Psychiatric Genomics Consortium, “Biological insights from 108 schizophrenia-associated genetic loci,” Nature, vol. 514, pp. 42–47, 2014.

[6] F. S. Goes, J. Mcgrath, D. Avramopoulos et al., “Genome-wide association study of schizophrenia in Ashkenazi Jews,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 168, no. 8, pp. 649–659, 2015.

[7] G. Donohoe, J. Walters, A. Hargreaves et al., “Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253,” Genes, Brain and Behavior, vol. 12, no. 2, pp. 203–209, 2013.

[8] E. Koiliari, P. Roussos, E. Pasparakis et al., “The CSMD1 genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males,” Schizophrenia Research, vol. 154, no. 1-3, pp. 42–47, 2014.

[9] E. T. Cirulli, D. Kasperevičiūt, D. K. Attix et al., “Common genetic variation and performance on standardized cognitive tests,” European Journal of Human Genetics, vol. 18, no. 7, pp. 815–820, 2010.

[10] V. A. Stepanov, A. V. Bocharova, A. V. Marusin, N. G. Zhukova, V. M. Alifárov, and I. A. Zhukova, “Replicative association analysis of genetic markers of cognitive traits with Alzheimer’s disease in the Russian population,” Journal of Molecular Biology, vol. 48, no. 6, pp. 835–844, 2014.

[11] A. V. Bocharova, V. A. Stepanov, A. V. Marusin et al., “Association study of genetic markers of schizophrenia and its cognitive endophenotypes,” Russian Journal of Genetics, vol. 53, no. 1, pp. 139–146, 2017.

[12] K. M. Hayden, O. A. Makeeva, L. K. Newby et al., “A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial,” Alzheimer’s & Dementia, vol. 10, no. 6, pp. 760–768, 2014.

[13] O. A. Makeeva, H. R. Romero, V. V. Markova et al., “Vascular risk factors confer domain-specific deficits in cognitive performance within an elderly Russian population,” Alzheimer’s & Dementia, vol. II, no. 7, pp. F894–F895, 2015.

[14] V. A. Stepanov and E. A. Trifonova, “Multiplex genotyping of single nucleotide polymorphisms by MALDI-TOF mass-spectrometry: frequencies of 56 SNP in immune response genes in human populations,” Molekularna Biologija, vol. 47, no. 6, pp. 976–986, 2013.

[15] K. Ohi, R. Hashimoto, H. Yamamori et al., “The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia,” Behavioral and Brain Functions, vol. 9, no. 1, article 40, 2013.

[16] Y. Liu, Z. Cheng, J. Wang et al., “No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population,” BMC Psychiatry, vol. 16, no. 1, article 206, 2016.

[17] L. Athanasius, S. Giiddaluru, C. Fernandes et al., “A genetic association study of CSMD1 and CSMD2 with cognitive function,” Brain, Behavior, and Immunity, vol. 61, pp. 209–216, 2017.

[18] V. A. Stepanov, A. V. Bocharova, K. Z. Saduakassova et al., “Replicative study of susceptibility to childhood-onset schizophrenia in Kazakhs,” Russian Journal of Genetics, vol. 51, no. 2, pp. 185–192, 2015.

[19] R. Sherva, Y. Tripodis, D. A. Bennett et al., “Genome-wide association study of the rate of cognitive decline in Alzheimer’s disease,” Alzheimer’s & Dementia, vol. 10, no. 1, pp. 45–52, 2014.

[20] S. Sakamoto, M. Takaki, Y. Okahisa et al., “Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes,” Journal of Human Genetics, vol. 61, no. 4, pp. 329–334, 2016.

[21] E. J. Rose and G. Donohoe, “Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia,” Schizophrenia Bulletin, vol. 39, no. 3, pp. 518–526, 2013.

[22] E. J. Rose, D. W. Morris, A. Hargreaves et al., “Neural effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 162, no. 6, pp. 530–537, 2013.